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Abstract: Deregulated BCR-ABL tyrosine kinase (TK) activity is the molecular marker for 
chronic myeloid leukemia (CML), which provides an identiﬁ  able target for developing therapeutic 
agents. Imatinib mesylate, a BCR-ABL TK inhibitor, is the frontline therapy for CML. Despite 
the stunning efﬁ  cacy of this agent, a small number of patients develop a suboptimal response 
or resistance to imatinib. In newly diagnosed patients with chronic phase CML, the rate of 
resistance to imatinib at 4 years was up to 20%, increasing to 70% to 90% for patients in the 
accelerated/blastic phase. Resistance to imatinib led to the development of novel TK inhibitors 
such as dasatinib. Several clinical trials have reported more durable complete hematologic and 
cytogenetic responses with this agent in patients who are resistant or intolerant to imatinib. 
Dasatinib is well tolerated and has broad efﬁ  cacy, resulting in durable responses in patients 
with any BCR-ABL mutation except for T3151 and mutations in codon 317 – most commonly 
F317L – including mutations that were highly resistant to imatinib, such as L248, Y253, E255, 
F359, and H396. Dasatinib is recommended for CML in chronic, blastic or accelerated phase 
that is resistant or intolerant to imatinib. Dasatinib was approved by the FDA at 100 mg once 
daily as the starting dose in patients with chronic phase CML and at 70 mg twice daily in patients 
with accelerated or blastic phase CML. Various clinical trial results provided evidence that 
resistance to one TK inhibitor can be reversed with the use of a different TK inhibitor (TKI). 
Other second-generation TKIs with activity in CML include nilotinib, bosutinib and INNO 406. 
New molecules, such as the inhibitor of Aurora family serine-threonine kinases, MK0457, which 
has antileukemic activity in CML associated with a T315I mutation, are being investigated. 
Allogeneic hematopoietic stem cell transplantation remains an option for selected patients.
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Introduction
Chronic myeloid leukemia (CML) accounts for 20% of all adult leukemias, approximately 
4300 cases per year in the United States, with a median patient age of 45 to 55 years. 
Most patients are diagnosed in the chronic phase and can progress to the accelerated or 
blastic phase, which is associated with decreased survival.1 The characteristic cytogenetic 
abnormality underlying CML is the Philadelphia chromosome (Ph), which corresponds 
to the reciprocal translocation between chromosomes 9 and 22. This translocation causes 
the Abelson tk gene (Abl) to fuse with the breakpoint cluster region of the Bcr gene.
The BCR-ABL oncogene triggers intracellular signaling, activating multiple 
transduction cascades, promoting the growth, proliferation and survival of 
hematopoietic cells.2 BCR-ABL plays a role in defective DNA repair, alteration of 
cellular adhesion and inhibition of apoptosis.3
Inhibiting BCR-ABL tyrosine kinase activity leads to the induction of apoptosis 
and inhibits cellular proliferation in vitro.4 Degregulated BCR-ABL tyrosine kinase 
activity is the molecular marker for CML, which provides an identiﬁ  able target for 
developing therapeutic agents. Various BCR-ABL isoforms with diverse molecular 
weights have been identiﬁ  ed. The weights range from 185 to 230 kDa depending on the 
translocation breakpoints in the Bcr gene and the mRNA splicing site.5 The 210 kDa 
BCR-ABL protein is the most common Bcr breakpoint in CML.Therapeutics and Clinical Risk Management 2009:5 282
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Imatinib mesylate
Imatinib mesylate (Gleevec®; Novartis Pharma, East Hanover, 
NJ, USA) is a very speciﬁ  c inhibitor of BCR-ABL tyrosine 
kinase activity of the 2-phenylamino pyrimidine class, and it 
is approved by the Food and Drug Administration as frontline 
therapy for patients with CML.6 Imatinib acts by binding and 
stabilizing the inactive form of BCR-ABL, thereby inhibit-
ing its autophosphorylation and the phosphorylation of its 
substrate, abrogating proliferation and inducing apoptosis of 
BCR-ABL–positive cells.4,7 The superiority of imatinib for 
successful clinical outcomes of patients with CML was con-
ﬁ  rmed by the International Randomized Study of Interferon 
plus low-dose cytarabine, the previous standard of care, vs 
STI571, or the imatinib (IRIS) trial, in which 553 patients 
were randomized to each arm.8 Imatinib induced high rates 
of complete hematologic response (96% at 1 year, which 
increased to 98% at 5 years),8 a major cytogenetic response 
(86% at 1 year, which increased to 92% at 5 years), a complete 
cytogenetic response (69% at 1 year and 87% at 5 years), a 
progression-free survival rate without accelerated or blast 
crisis (93% at 6 years), overall progression-free survival (83% 
at 6 years) and overall survival (95% at 6 years, taking into 
consideration only CML-related deaths; and 88% at 6 years 
when deaths from any cause were included).8–10
However, a small number of patients develop a subopti-
mal response or resistance to imatinib. In newly diagnosed 
patients with chronic phase CML, the rate of resistance to 
imatinib at 4 years was 20%, increasing to 70% to 90% for 
patients in the accelerated/blastic phase.8 Criteria for failure 
to respond to imatinib have been deﬁ  ned as no hematologic 
response at 3 months, incomplete hematologic response or no 
cytogenetic response at 6 months, less than a partial cytoge-
netic response at 12 months, less than a complete cytogenetic 
response at 18 months, and in the case of a hematologic or 
cytogenetic response, loss, or appearance of highly imatinib-
resistant BCR-ABL mutations. A suboptimal response was 
deﬁ  ned as an incomplete hematologic response at 3 months, 
less than a partial cytogenetic response at 6 months, less than 
a complete cytogenetic response at 12 months, less than a 
major molecular response at 18 months, and, in the case of 
a major molecular response, loss of BCR-ABL, other muta-
tions or other chromosomal abnormalities.11
Resistance to imatinib is primary (no response after initial 
treatment) or secondary (after an objective response has been 
achieved). The latter has been attributed to point mutations 
in the kinase domain of BCR-ABL consisting of amino-acid 
substitutions that impair imatinib binding but retain kinase 
activity.12 The T315I mutation in the ATP binding pocket 
of the ABL tyrosine kinase with its single amino acid 
substitution of the threonine 315 residue with isoleucine 
was initially reported to cause resistance to imatinib and 
later to dasatinib.13 However, in 2005, more than 30 point 
mutations composed of single amino acid substitutions in the 
BCR-ABL kinase domain were identiﬁ  ed in patients with 
relapsed disease. Additionally, the proportion of mutations 
in the late chronic phase of CML and accelerated or blastic 
phases range from 22% to 53%, whereas such mutations 
occur infrequently in the early chronic phase.14 A decrease in 
sensitivity to imatinib from threefold to greater than 100-fold 
has been seen after kinase domain mutations reactivate the 
kinase activity of the BCR-ABL fusion protein.
Other mechanisms of resistance to imatinib include 
alteration of the balance favoring the active state of ABL 
kinase, shifting the equilibrium between active and inactive 
states;15 a change in the conformation of the BCR-ABL 
protein, preventing imatinib from directly binding to its 
binding site;16 ampliﬁ  cation of the BCR-ABL gene, leading 
to over-expression of BCR-ABL protein, as detected by 
FISH;13,16 or over-expression of the P-glycoprotein efﬂ  ux 
pump, for which imatinib is the substrate.17,18 Additional 
mechanisms include the binding of the A1 acid glycoprotein 
(AGP) to imatinib in plasma, reducing its intracellular con-
centrations,19 or a less understood mechanism, the inhibition 
of ABCG2 protein functionality by imatinib.20
Independent BCR-ABL cytogenetic mutations can also 
contribute to imatinib resistance, including aneuploidy, 
reciprocal translocations, and 17p mutations, which lead to 
the loss of one p53 allele.16 Dasatinib was one of the newer 
tyrosine kinase inhibitors (TKIs) whose development was 
geared toward overcoming imatinib resistance.
Dasatinib
Dasatinib (BMS-354825, Sprycel®; Bristol Myers Squibb, 
New York, NY, USA) is a potent, second-generation, 
small-molecule, multitarget kinase inhibitor of BCR-ABL. 
This agent exerts greater in vitro activity against unmutated 
ABL kinase than imatinib. Dasatinib was initially developed 
as an inhibitor of the Src family of kinases such as Fyn, Yes, 
Src, and Lyk, but it also inhibits BCR-ABL, EphA2, platelet-
derived growth factor receptor, and c-Kit. Additionally, it 
binds to other tyrosine and serine/threonine kinases such 
as the mitogen-activated protein kinases and the receptor 
tyrosine kinase, discoidin domain receptor 1.21 Dasatinib can 
inhibit the proliferation and kinase activity of wild-type and 
BCR-ABL mutant cell lines that are resistant to imatinib, 
except those carrying the T315I mutation.22,23 In vivo studies Therapeutics and Clinical Risk Management 2009:5 283
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have shown that dasatinib is 325-fold more potent than 
imatinib and 16-fold more potent than nilotinib, another 
BCR-ABL kinase inhibitor, against unmutated BCR-ABL.24 
In murine models dasatinib was shown to inhibit leukemic 
cell growth and to prolong the survival of mice harboring 
wild-type BCR-ABL and M351T, but not the T315I mutant.22 
Dasatinib is a dual-speciﬁ  c Src and Abl inhibitor that can 
inhibit both the active and inactive conformations of ABL.22 
Recently, the activity of dasatinib against 18 imatinib-resis-
tant BCR/ABL mutants in comparison with two other TKIs 
(nilotinib and bosutinib) was investigated.25 Dasatinib was 
shown to compare favorably to nilotinib against 252 and 253 
mutants, which are common in imatinib-resistant patients.26,27 
Also, it was active against the H396P/R mutation in the 
activation loop or F359F in the active site. In contrast, it was 
less active than bosutinib for Q252H and L384M.25 In June 
2006, the Food and Drug Administration approved dasatinib 
for the treatment of chronic phase, accelerated phase, or 
blastic phase CML, resistant or intolerant to imatinib, and 
for Ph chromosome-positive acute lymphoid leukemia that 
was resistant or intolerant to prior therapy.28
Mechanism of action
Dasatinib binds to the ATP-binding site, but extends in the 
opposite direction from imatinib. Dasatinib binds the inac-
tive and active conformation of the ABL kinase domain, 
requires fewer contact points with ABL, and has a greater 
afﬁ  nity to the ABL kinase domain compared to imatinib. 
In vitro, dasatinib has demonstrated greater than 325-fold 
activity against BCR-ABL wild-type,23 and the kinase activity 
of 14 of 15 BCR-ABL imatinib-resistant isoforms has been 
successfully inhibited at nanomolar concentrations of 
dasatinib.22,23 The activity of dasatinib against several ABL 
kinase mutations is explained by the fact that it does not 
require interaction with some of the residues involved in 
those mutations. Dasatinib’s inhibiting potential against Src 
family kinase members is greater (IC50 0.5 nmol/L) than its 
inhibitory activity against ABL (1 nmol/L).29 At nanomolar 
concentrations, dasatinib also inhibits c-KIT, platelet-derived 
growth factor receptor and EphA2. Potent Src inhibitory 
activity of dasatinib in CML progenitors involves BCR-
ABL–dependent and BCR-ABL–independent Src activity.30 
Dasatinib also inhibits downstream signaling pathways in 
CML progenitors,30 as well as P-mitogen-activated protein 
kinase (MAPK), P-Akt, and P-STAT5 levels in CML progen-
itors in the absence but not in the presence of growth factors. 
In addition, dasatinib signiﬁ  cantly suppressed CML colony-
forming cells and long-term culture-initiating cells.30
Recently, dasatinib-induced BCR-ABL inhibition was 
shown to be sufﬁ  cient to commit chronic myeloid leukemia 
cells irreversibly to apoptosis and suggested that in patients 
with CML receiving dasatinib once daily, response cor-
relates with the magnitude of BCR-ABL kinase inhibition, 
demonstrating the potential clinical utility of intermittent 
potent kinase inhibitor therapy.31
Dasatinib was also shown to signiﬁ  cantly suppress CML 
colony-forming cells and long-term culture-initiating cells, but 
it did not signiﬁ  cantly alter the level of apoptosis-regulating 
proteins in CML CD34 + cells.30 Therefore, dasatinib suppresses 
progenitor growth through inhibition of proliferation and a 
modest increase in apoptosis in dividing progenitors.30 In 
addition, dasatinib did not enhance suppression and targeting 
of CML primitive and committed progenitors.30
Dasatinib was shown to signiﬁ  cantly inhibit CrKL phos-
phorylation and to be more effective than imatinib mesylate 
by targeting an earlier progenitor population than imatinib, 
but without affecting the most primitive quiescent CML cells, 
which appeared to be resistant to both drugs.32
An intriguing observation is that dasatinib may modulate 
or suppress T-cell activation and proliferation.24 In a series 
of 18 patients treated with dasatinib, 8 patients developed 
chronic peripheral lymphocytosis, evidenced by natural killer 
(NK) cells or natural killer/T [NK/T]-cells with large granu-
lar lymphocyte morphologies and expression of CD16(+), 
CD56(+), CD3(–) or CD3(+). More importantly, all patients 
who developed large granular lymphocyte lymphocytosis 
achieved optimal molecular responses (8/8 in large granular 
lymphocytes (+) cases vs 3/10 in large granular lymphocytes 
(–) cases, p = 0.002). In addition, NK cell cytotoxicity in 
dasatinib responders was superior to that in non-responders. 
These ﬁ  ndings may have implications for treatment, as large 
granular lymphocytes might have a therapeutic effect on 
Ph(+) leukemic cells.24
Potential mechanisms for the pathogenesis of large 
granular lymphocytes after dasatinib therapy include the 
reduction of BCR/ABL transcription by TKIs and restoration 
of NK cell numbers and/or functions, and direct activation 
or modulation of the proliferation and function of LGLs.33 
However, it is still unclear whether the effect of dasatinib on 
NK or NK/T cell proliferation or activation is mediated via 
Src kinase or other unknown potential pathways involved in 
the proliferation and differentiation of NK or NK/T cells.33
Pharmacokinetics
Dasatinib is administered orally and peaks from 0.5 to 6 hours 
after oral dosing. Its half-life is 3 to 5 hours and the absorption Therapeutics and Clinical Risk Management 2009:5 284
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is not affected by food intake. Dasatinib is metabolized by 
the cytochrome P450 (CYP) 3A4 isozyme into active and 
inactive metabolites. Therefore, concomitant use of dasatinib 
with inducers of CYP3A4 can decrease dasatinib exposure, 
whereas inhibitors of the 3A4 enzyme, such as antiretrovirals, 
azole antifungals and macrolides, can increase the toxicity 
of dasatinib. Recent data suggest that dasatinib given orally 
crosses the blood–brain barrier. The concentrations of 
dasatinib found in the cerebrospinal ﬂ  uid of patients ranged 
from 1.4 to 20.1 nM, and were consistent with the observed 
antitumor activity in the central nervous system.34
Dasatinib was shown to have a high intrinsic permeability 
in Caco-2 cells, ie, cells derived from a human colon 
carcinoma, and their growth forms a conﬂ  uent monolayer 
on a semipermeable membrane, polarized to resemble the 
intestinal epithelium.35 Although the efﬂ  ux ratio indicated 
that dasatinib might be a substrate for an intestinal efﬂ  ux 
transporter, in vivo studies in P-gp knockout mice vs wild-
type mice showed no difference in the amount of dasatinib 
remaining unabsorbed in the gastrointestinal tract, suggest-
ing that P-gp may not be responsible for the incomplete 
bioavailability.35
In addition, although the ability of the ABC transporter 
protein ABCG2 to transport TKIs is controversial, some 
investigators have shown that TKIs can inhibit transporter 
molecules on primary stem cells.36
The elimination of dasatinib is primarily via the feces. 
The concomitant use of H2 blockers and proton pump inhibi-
tors is not recommended since the solubility of dasatinib 
depends on intestinal pH, and therefore, anti-acid agents 
reduce the concentration of dasatinib by approximately 60%. 
No clinically relevant data are available for dose modiﬁ  ca-
tions based on age, gender or ethnicity, although patients 
greater than 65 years showed increased ﬂ  uid retention over 
younger patients. More importantly, the efﬁ  cacy of dasatinib 
appears to be independent of patient age.
Clinical trials
Phase I trials
In a phase I study dasatinib was administered in 84 patients 
with CML or Ph(+) ALL who were resistant or intolerant 
to imatinib, at doses ranging from 15 to 240 mg/day, orally 
once or twice daily over a 4-week treatment cycle (Table 1). 
The response rate was dependent on the CML phase. In 
chronic phase CML, the rates of complete major hemato-
logic response and major cytogenetic response were 92% 
and 45%, respectively. The respective rates in patients with 
accelerated phase CML were 82% and 27%. Eighty percent 
of CML patients with lymphoid blastic crisis or Ph(+) ALL 
had a major hematologic response and a major cytogenetic 
response. Overall, 95% of patients in the chronic phase 
had a durable response compared with 82% of patients 
in the accelerated phase. However, within 6 months of 
therapy, almost all patients with Ph(+) ALL had relapsed. 
All BCR-ABL genotypes, with the exception of those with 
the T315I mutation, responded to dasatinib. The most com-
mon toxicity, although not dose-limiting, was reversible 
myelosuppression. The maximum tolerated dose was not 
determined; however, most of the complete hematologic 
responses were noted at daily doses of dasatinib of 50 mg, 
whereas most cytogenetic responses were noted at higher 
doses.37 The encouraging results of this phase I study led 
to studies comparing the efﬁ  cacy of dasatinib with imatinib 
and other trials.
Phase II trials
The effects of dasatinib in different stages of CML and 
Ph(+) ALL were explored in the START (Src/ABL Tyrosine 
Kinase Inhibition Activity Research Trials of dasatinib) 
Program, which included 5 arms: START-A (accelerated 
phase), START-B (myeloid blast crisis), START-C (chronic 
phase), START-L (lymphoid blast crisis), and START-R 
(dasatinib vs high-dose imatinib) (Table 1). Preliminary 
results of 4 of the 5 single arm phase II studies (A, B, C 
and L) constituted the basis for the new drug application 
for the indication of dasatinib in CML. These four single-
arm, multicenter studies led to the approval of dasatinib by 
the FDA and included a total of 445 patients with CML in 
accelerated phase, myeloid phase, and lymphoid blast phase, 
and Ph(+) ALL, who were resistant or intolerant to prior 
therapy, including imatinib.28 Dasatinib was administered 
at an initial dose of 70 mg po twice daily and escalation 
to 100 mg po twice daily was permitted in the absence of 
a signiﬁ  cant toxicity. Escalation was recommended for 
increasing leukocyte counts, lack of complete hematologic 
remission within 1 month from initiation of therapy, lack of 
complete cytogenetic response after 3 months of therapy, and/
or loss of response. In chronic phase CML (endpoint, major 
cytogenetic response), the major cytogenetic response rate 
was 45% with a complete cytogenetic response rate of 33%; 
and in accelerated phase CML, myeloid CML, lymphoid 
blast CML, and Ph(+) ALL (endpoint, major hematologic 
response), the rates of major hematologic response were 
59%, 32%, 31% and 42%, respectively.28 As expected, the 
response rates were higher in patients who were intolerant to 
imatinib than in those who were imatinib-resistant.28Therapeutics and Clinical Risk Management 2009:5 285
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In the open label, phase II (START-A) study of patients 
with accelerated phase CML who were resistant or intolerant 
to imatinib, dasatinib 70 mg po twice daily was adminis-
tered in 107 patients.38 At 8 months, the rate of hematologic 
response was 81% (major 64%, complete 39%). The rates 
of major and complete cytogenetic response were 33% and 
24%, respectively. At 8 months, of 69 patients who achieved 
a major cytogenetic response, 7 progressed and the estimated 
rates of survival and progression-free survival were 76% 
each. Severe neutropenia was noted in 76% of patients, 
thrombocytopenia in 82%, and anemia in 69%. Cytopenias 
were reversible with dose reduction or interruption.38
The study arms START-B and START-L accrued patients 
with imatinib-resistant/intolerant CML in myeloid blast crisis 
(n = 74) or imatinib-resistant/intolerant CML in lymphoid 
blast crisis (n = 42), respectively.39 The starting dasatinib 
dose was 70 mg bid; patients with a poor initial response 
were treated with doses up to 100 mg bid, whereas the dose 
was reduced to 50 mg bid and then to 40 mg bid in patients 
who experienced toxicity. At 8 months, dasatinib induced 
major hematologic response rates of 34% in the START-B 
trial and 31% in the START-L trial. Respective rates of major 
cytogenetic response were 31% and 50%. Eighty-six percent 
of major cytogenetic responses were complete cytogenetic 
responses. At 8 months, the rates of progression-free survival 
were 88% in the START-B arm and 46% in the START-L 
arm.39 In both studies the most likely cause of discontinuation 
of therapy was disease progression followed by study drug 
toxicity in the START-B trial and death in the START–L 
trial. Patients with BCR-ABL mutations E255K, T312I 
and F486S did not respond to dasatinib. The hematologic 
responses were durable, and dasatinib was well tolerated 
except for hematologic toxicity that was reversible with dose 
interruption or dose reduction.39
In the START-C arm 186 patients in chronic phase CML 
who were resistant to imatinib 600 mg/day or intolerant 
to imatinib secondary to adverse events were treated with 
dasatinib 70 mg po twice daily.40 With a median duration 
of dasatinib therapy of 8 months, the rates of complete 
hematologic and major cytogenetic response were 90% 
and 52%, respectively. Major cytogenetic responses were 
maintained in 96% to 100% of patients. More impor-
tantly, dasatinib induced molecular responses and reduced 
BCR-ABL/ABL transcript ratios from 66% at baseline to 
2.6% at 9 months. The most common toxicity was myelo-
suppression. Responses were noted in patients with several 
BCR-ABL mutations except for the T315I mutation. With 
a minimum follow-up of 8 months, the progression-free 
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survival rate was 92%, and 9% of patients discontinued 
therapy because of adverse events.40
In the START-R arm in patients with imatinib-resistant, 
chronic phase CML, patients were randomized 2:1 to 
receive dasatinib 70 mg po bid (n = 101) or imatinib 
400 mg po bid (n = 49).41 Dasatinib therapy induced higher 
rates of complete hematologic response (93% vs 82%, 
respectively; p = 0.034), major cytogenetic response (52% 
vs 33%, respectively; p = 0.023), and complete cytogenetic 
response (40% vs 16%; p = 0.004) compared with imatinib. 
With a median follow-up of 15 months, dasatinib was also 
associated with lower rates of treatment failure (p  0.001) 
and higher rates of progression-free survival (p  0.001) 
compared with imatinib. Dasatinib was also associated 
with a higher incidence of pleural effusion (17% vs 0% 
with imatinib), whereas imatinib was associated with 
higher rates of superﬁ  cial edema (42% vs 15%) and ﬂ  uid 
retention (45% vs 30%).41 Cytopenias were more frequent 
and severe with dasatinib. These results suggested that for 
patients in the chronic phase of CML who did not respond 
to the standard imatinib dose, dasatinib was an extremely 
effective treatment option.41
In an interim analysis of another phase II study, dasatinib 
140 mg/day po was given to 36 patients with imatinib-
resistant or imatinib-intolerant Ph(+) ALL and CML in 
lymphoid blast crisis.42 With a minimum follow-up of 
8 months, dasatinib resulted in a major hematologic response 
in 42% of patients, 67% of whom remained progression free, 
and resulted in a complete cytogenetic response in 58% of 
patients. Overall, 6% (2/36) of patients discontinued therapy 
as a result of adverse events, with the most common severe 
adverse event being febrile neutropenia.42
Phase III trials
A phase III trial explored whether dasatinib administered 
twice daily would be better tolerated compared to daily 
dosing (Table 1). Overall, 670 imatinib-resistant or -intoler-
ant patients with chronic phase CML were randomized into 
4 treatment arms: 100 mg daily, 50 mg twice daily, 140 mg 
once daily, and 70 mg twice a day. Response rates were com-
parable among the four arms. The rates of major cytogenetic 
response ranged from 54% to 59% and complete cytogenetic 
responses ranged from 41% to 45% across the four arms. The 
hematologic response rate ranged from 86% to 92%. There 
were no signiﬁ  cant differences in progression-free survival, 
time to response and duration of cytogenetic response among 
the four arms. The daily 100 mg dose was associated with 
a lower incidence of toxicities, such as pleural effusion, 
and thrombocytopenia and with fewer dose interruptions 
compared with the 70 mg po twice daily dose.43
Based on these ﬁ  ndings, dasatinib was approved by the 
FDA at 100 mg po once daily in patients with chronic phase 
CML and at 70 mg po twice daily in patients with accelerated 
or blastic phase CML.
Other studies
Dasatinib has also shown activity in patients with CML who 
failed nilotinib therapy. In a retrospective analysis of dasat-
inib in patients with all phases of CML, who failed imatinib 
and nilotinib therapy, 23 patients were treated with dasatinib 
140 mg/day (except for one patient, 240 mg/day).44 The 
response rate to dasatinib was 57%. The complete hemato-
logic response was 43% (30% of whom achieved a cytoge-
netic response, including 2 complete cytogenetic responses). 
None of the two patients with the T315I mutation responded 
to dasatinib. After a median follow-up of 34 weeks, 30% of 
patients died and 48% continued on dasatinib therapy. These 
results provided evidence that resistance to one TKI can be 
reversed with the use of a different TKI.44
Mutational analysis
Patients resistant to TKIs frequently bear point mutations 
within the ABL kinase domain of the BCR-ABL fusion 
protein. The most frequent mutations are located in the 
ATP-binding loop, namely the P-loop. These mutations are 
thought to have greater oncogenic activity compared to other 
mutations and wild-type BCR-ABL. Dasatinib has marked 
activity in patients resistant to imatinib, including those 
with mutations within the P-loop. Evolving data suggest that 
dasatinib may be more effective than nilotinib in patients 
bearing P-loop mutations.45
Methods used for mutational analysis include direct 
sequencing (sensitivity, 20% to 25%); pyrosequencing 
(sensitivity, 1%–5%); quantitative mutation-speciﬁ  c RQ-PCR 
(sensitivity, 0.01%–0.1%); and liquid bead-array (sensitivity, 
5%–10%). Other methods include denaturing high perfor-
mance liquid chromatography, targeted microarrays, and 
liquid bead arrays.46 Quantitative mutation detection assays 
such as PCR-based pyrosequencing and mutation-speciﬁ  c 
quantitative PCR, as well as digital PCR applications using 
microﬂ  uidic separation, have also been used. The quantitative 
methods are used to monitor clinical outcomes with the novel 
TKIs, particularly against the T315I mutation.46
Indications for BCR-ABL kinase domain mutational 
analysis include (a) inadequate initial response to TKIs or 
evidence of loss of response and (b) advanced phase CML or Therapeutics and Clinical Risk Management 2009:5 287
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progression to accelerated or blast phase CML. Mutational 
analysis could be repeated in these patients if they fail to 
respond to a TKI or if having responded, they subsequently 
have rising numbers of BCR-ABL transcripts.47 Some 
investigators recommend the use of mutational analysis for 
a 10-fold increase in BCR-ABL transcript levels, although 
smaller rises in BCR-ABL transcript levels alone may also 
be predictive of mutation development. However, increasing 
BCR-ABL transcript levels alone is not a standard crite-
rion because standardization of BCR-ABL RQ-PCR is not 
optimized.46
In a recent report of mutational analysis performed in 
1043 patients with CML treated with dasatinib, dasatinib 
demonstrated broad efﬁ  cacy, resulting in durable responses 
in patients with any BCR-ABL mutation except for T315124 
(pre-existence or selection of the T315I mutant constitutes 
the most common mechanism of resistance to dasatinib).48 
Of 1043 patients, 402 (39%) had a BCR-ABL mutation. 
The proportion of patients with a BCR-ABL mutation was 
higher among patients with imatinib resistance (48% of 805) 
compared with imatinib-intolerant patients (8% of 238). 
The investigators reported high response rates and durability 
of responses in patients with mutations that were highly resis-
tant to imatinib, such as L248, Y253, E255, F359, and H396. 
The efﬁ  cacy of dasatinib was also shown in patients with 
any of these 5 imatinib-resistant mutations with a dasatinib 
cellular IC50  3 nM, excluding T315I. More interestingly, 
patients bearing mutations with a dasatinib IC50  3 nM or 
unknown IC50 had similar response rates and durability of 
response to those without a BCR-ABL mutation. Responses 
in patients with a T315I mutation were rare (IC50  200 nM; 
n = 21). Overall, 162 patients were followed with mutational 
analysis: 26% retained a BCR-ABL mutation, 26% lost a 
mutation, 27% developed a mutation, and the remaining 
belonged to  1 mutational category.24
Interestingly, F317L is another emerging mutation that 
has been observed in dasatinib-resistant patients.48 In addi-
tion, although dasatinib signiﬁ  cantly inhibits CrkL phosphor-
ylation and reduces the total number of CD34+ CD38− CML 
cells compared to imatinib, it does not appear to eliminate 
the most quiescent fraction of stem cells.32,49
Toxicity
Dasatinib is generally well tolerated. The most common 
non-hematologic adverse events in clinical trials with 
dasatininb included gastrointestinal symptoms, such as 
diarrhea, nausea, vomiting, anorexia, abdominal pain and 
anorexia; headache; peripheral edema; and pleural effusion. 
Fewer than 10% of patients reported mucositis, stomatitis, 
abdominal distention, constipation, colitis, dysphagia, 
anal ﬁ  ssure, upper gastrointestinal ulcers, pancreatitis and 
esophagitis. Pleural and pericardial effusion, severe pulmo-
nary edema, pulmonary hypertension, and ascites were less 
common. Ascites and pleural effusion are usually reversible 
with temporary dose interruption, diuretics and steroids.
Myelosuppression is common and it is reversible 
by interruption, reduction or discontinuation of the 
myelosuppression-inducing dasatinib dose. Grade 3–4 myelo-
suppression is more frequent in patients with accelerated or 
blastic phase CML and constitutes the most common reason 
for drug interruption. Thrombocytopenia is more signiﬁ  cant 
than neutropenia and its associated rates of gastrointestinal 
bleeding and central nervous system hemorrhage are 4% 
and 1%, respectively, whereas the rate of other severe 
hemorrhages is approximately 2%. Dasatinib-induced throm-
bocytopenia associated with hemorrhagic complications 
suggests that patients receiving anticoagulation or antiplatelet 
agents should be treated with caution.
Cardiac adverse events are infrequent and include left 
ventricular dysfunction, cardiac failure, cardiomyopathy, 
ventricular failure, diastolic dysfunction, and QT-interval 
prolongation. Skin sequelae include erythema, erythema 
multiforme, pustular rash, pruritic rash, skin exfoliation, 
skin irritation, systemic lupus erythematous, vesicular 
rash, and maculopapular rash. Fewer than 10% of patients 
develop acne, alopecia, skin ulcer, pigmentation disorder, 
panniculitis, photosensitivity, nail disorders, and palmar 
plantar erythrodysesthesia.
The use of dasatinib is also associated with hypocalcemia, 
hypophosphatemia, transaminitis and creatinine eleva-
tion. Symptoms from the central nervous system are noted 
in 10% of patients and include neuropathy, dizziness, 
dysgeusia, somnolence, tremor, syncope, transient ischemic 
attack, cerebrovascular disease and seizures. Other toxicities 
include hypersensitivity, gynecomastia, irregular menses, 
vertigo, appetite disturbances, increased triglycerides, cho-
lesterol, pyrexia and fatigue.
Hematopoietic stem cell transplantation
The use of TKIs has limited the use of this previously 
commonly used therapeutic strategy in CML. According to 
the 2009 NCCN recommendations, hematopoietic stem cell 
transplantation should be offered as an option to patients 
who (a) have no cytogenetic response at 6 months, (b) have 
cytogenetic relapse at 12 and 18 months following initial 
hematologic remission, (c) have partial cytogenetic response Therapeutics and Clinical Risk Management 2009:5 288
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at 18 months and (d) have T315I mutation and failed to 
respond to imatinib, dasatinib or nilotinib.
Future studies
Dasatinib has been shown to synergize with novel TKIs in 
producing growth inhibition and apoptosis in CML cells.50 
Therefore, carefully designed clinical trials with combined 
TKIs may improve the prognosis of imatinib-resistant CML. 
For instance, patients with imatinib-resistant CML and 2 sub-
clones, one carrying F359V and the other F317L, could 
beneﬁ  t from a combination therapy of dasatinib plus nilotinib, 
if hematopoietic stem cell transplantation is not an option.
Conclusion
Dasatinib is an effective therapy for patients with CML. It 
is more effective than high-dose imatinib in patients who 
failed standard dose imatinib. Because dasatinib enters the 
central nervous system, patients whose disease relapses in the 
central nervous system may beneﬁ  t from dasatinib. However, 
new agents are needed for patients with a T3151 mutation, 
since patients with this mutation are resistant to dasatinib. 
Other second-generation TKIs with activity in CML include 
nilotinib, bosutinib and INNO 406. New molecules, such 
as the inhibitor of Aurora family serine-threonine kinases, 
MK0457, which has antileukemic activity in CML associated 
with the T315I mutation, are being investigated in CML.
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